Schedule 13G Filing by The Vanguard Group for Ironwood Pharmaceuticals Inc.

This filing is an amendment to a Schedule 13G filed by The Vanguard Group concerning Ironwood Pharmaceuticals Inc. The filing indicates that as of March 13, 2026, The Vanguard Group, an investment advisor, does not hold a significant beneficial ownership in Ironwood Pharmaceuticals Inc. The report states that the number of shares beneficially owned is 0, with 0% ownership. Item 5 and Item 6 of the filing note that the reporting person is not a 5% owner and that while certain investment companies and managed accounts have the right to dividends or sale proceeds, no single other person has more than a 5% interest. The filing also includes a certification stating that the securities were acquired in the ordinary course of business and not for the purpose of influencing control of the issuer. An internal realignment within The Vanguard Group on January 12, 2026, led to the disaggregation of beneficial ownership reporting for certain subsidiaries.